


Amendments to the Claims:

10/529776
JC17 Rec'd PCT/PTO 30 MAR 2005

This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

Claim 1. (Original) A compound of formula I



wherein

1) R_2 is a residue of formula



and

a) R_1 is thienyl, furyl, thiazolyl or 2-methyl-thiazolyl,

X is $-\text{CH}_2-$, and

R_3 is benzo[1,3]dioxol-yl or phenyl optionally monosubstituted by halogen,

or

b) R_1 is phenyl substituted by $-\text{SO}_2\text{CH}_3$ or CN

X is $-\text{CH}_2-$, and

R_3 is phenyl

or


c) R_1 is phenyl

X is a direct bond, and

R_3 is pyridyl,

or

2) R_2 is a residue of formula



and

a) R_1 is pyridyl, phenyl optionally substituted by carboxy or C_{1-4} alkoxycarbonyl, 2-methylthiazolyl, indolyl or benzimidazol-2-yl,

X₁ is -CH₂- or -CH₂-CH₂-, and

R₃ is phenyl optionally substituted by Hal,

or

b) R₁ is phenyl

X is a direct bond

R₃ is pyridyl,

or


c) R₁ is 2-methyl-thiazolyl,

X is -CH₂-, and

R₃ is 1-methyl-indolyl

or

3) R₂ is a residue of formula



and

a) R₁ is 2-methyl-thiazolyl

X is -CH₂-, and

R₃ is phenyl substituted by halogen

or


b) R₁ is pyridyl

X is a direct bond, and


R₃ is phenyl

or


4) R₂ is a residue of formula



or



or



wherein

Hal is F or Cl,

Z is -C= or -N=

and


a) R₁ is phenyl, X is a direct bond and R₃ is pyridyl

or

b) R₁ is pyridyl, X is a direct bond and R₃ is phenyl

or

5) R₂ is a residue of formula




wherein Y is --C= or --N=

and

R₁ is pyridyl, X is a direct bond and R₃ is phenyl,

or


6) R₂ is a residue of formula




X is a direct bond and one of R₁ and R₃ is phenyl and the other is pyridyl,

or

7) R₂ is a residue of formula




or




wherein each of R_a and R_b, independently, is H, CH₃ or C₂H₅, R₁ and R₃ are phenyl, and X is a direct bond

or

8) R₂ is a residue of formula



or




R₁ is pyridyl, X is a direct bond and R₃ is phenyl,

or

9) R₂ is indol-4-yl, R₁ is pyridyl, X is a direct bond and R₃ is phenyl, in free form or in salt form.

Claim 2. (Original) A process for the preparation of a compound of formula I as defined in claim 1 which process comprises

a) amidating a compound of formula II




wherein R₁, R₃ and X are as defined in claim 1

with a compound of formula III




wherein R₂ is as defined in claim 1, A is a leaving group, e.g. Cl or Br; or

b) reacting a compound of formula IV



wherein R₂ and R₃ are as defined in claim 1, with a compound of formula V



wherein R₁ and X are as defined above;

and, where required, converting the resulting compound of formula I obtained in free form into the desired salt form, or vice versa.

Claim 3. (Original) A compound of formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof for use as a pharmaceutical.

Claim 4. (Original) A pharmaceutical composition comprising a compound of formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable diluent or carrier therefor.

Claim 5. (Original) Use of a compound of formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof for the preparation of a medicament for preventing or treating a disorder or disease mediated by interactions between chemokine receptors and their ligands.

Claim 6. (Original) A pharmaceutical combination comprising a) a first agent which is a compound of formula I as defined in claim 1, in free form or in pharmaceutically acceptable salt form, and b) at least one co-agent.

Claim 7. (Original) A method for preventing or treating disorders or diseases mediated by interactions between chemokine receptors and their ligands in a subject in need of such

treatment, which method comprises administering to said subject an effective amount of a compound of formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof.

Claim 8. (Currently amended) A method ~~as defined in claim 7~~ for preventing or treating disorders or diseases mediated by interactions between chemokine receptors and their ligands in a subject in need of such treatment, comprising co-administration of a therapeutically effective non-toxic amount of a compound of formula I as defined in claim 1 and at least a second drug substance.